Adherence to tyrosine kinase inhibitors among Medicare Part D beneficiaries with chronic myeloid leukemia

E-ISSN： 1097-0142|124|2|364-373

ISSN： 0008-543x

Source： CANCER, Vol.124, Iss.2, 2018-01, pp. : 364-373

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Adherence to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: The Challenge That Lies Ahead

Acta Haematologica, Vol. 136, Iss. 1, 2016-05 ,pp. : 43-44

Karger

Access to resources Recommend Favorite

Medication Adherence to Tyrosine Kinase Inhibitors: 2-Year Analysis of Medication Adherence to Imatinib Treatment for Chronic Myeloid Leukemia and Correlation with the Depth of Molecular Response

Acta Haematologica, Vol. 136, Iss. 1, 2016-05 ,pp. : 45-51

Karger

Access to resources Recommend Favorite

Treating Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors

Acta Haematologica, Vol. 130, Iss. 3, 2013-06 ,pp. : 192-195

Karger

Access to resources Recommend Favorite

Adherence to Tyrosine Kinase Inhibitor Therapy for Chronic Myeloid Leukemia: A Brazilian Single-Center Cohort

Acta Haematologica, Vol. 130, Iss. 1, 2013-01 ,pp. : 16-22

Karger

Access to resources Recommend Favorite

Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors

CANCER, Vol. 121, Iss. 21, 2015-11 ,pp. : 3894-3904

John Wiley & Sons Inc

Access to resources Recommend Favorite